NEW YORK (GenomeWeb) – Dako, an Agilent Technologies company, today announced it has signed an additional collaboration with Amgen to develop a companion diagnostic for an unspecified Amgen cancer drug candidate.

In an email to GenomeWeb, Agilent declined to provide additional details about the agreement.

The deal builds on agreements from 2012 between the two companies, under which Dako was developing several companion diagnostics for drugs from Amgen.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.